

NOV 15 2006

(Use as many sheets as necessary)

1

of

1

Attorney Docket Number	046562/274660
------------------------	---------------

[illegible]


Foreign Patent Document						
Examiner Initials	Cite No.	Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
MG		WO 96/37202	11-28-1996	Alza Corp.		
Examiner Signature	/Michel Graffeo/			Date Considered	01/09/2007	

LEGAL02/30132815v1

Substitute for form 1449/PTO
(Revised 07/2005)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/805,977
Filing Date	March 22, 2004
First Named Inventor	Fraser
Group Art Unit	1614
Examiner Name	Not yet assigned
Attorney Docket Number	046562/274660

Sheet 1 of 1

U. S. PATENT DOCUMENTS




Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MG	1	US-2004-0142034	07-02-2004	Thor <i>et al.</i>	
↓	2	US-2005-0054725	03-10-2005	Thor <i>et al.</i>	
	3	US-2005-0228049	10-13-2005	Thor <i>et al.</i>	
	4	US-2006-0188571	08-24-2006	Thor <i>et al.</i>	
	5	US-2002-0239890	10-27-2005	Fraser <i>et al.</i>	
MG	6	US-2006-0247311	11-02-2006	Fraser <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached

Examiner Signature	/Michel Graffeo/	Date Considered	01/09/2007
--------------------	------------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<div style="display: flex; justify-content: space-around; align-items: center;"> <div>Substitute for form 1449/PTO (Revised 04/2003)</div> <div style="text-align: center;">  </div> </div> <div style="text-align: center; font-weight: bold; margin-top: 10px;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use as many sheets as necessary)</small> </div>				Complete if Known		
				Application Number	10/805,977	
				Filing Date	March 22, 2004	
				First Named Inventor	Landau	
				Group Art Unit	1614	
Examiner Name	Not yet assigned					
Sheet 1 of 1	Attorney Docket Number 046562/274660					
U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	
		US-				
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
MG	30	WO 96/37202	11-28-1996	Alza Corporation		
	31	WO 01/01983 A1	01-11-2001	Warner-Lambert Company		
	32	WO 01/24792 A1	04-12-2001	Warner-Lambert Company		
	33	WO 01/37832 A2	05-31-2001	Aventis Pharma S.A.		
	34	WO 03/000642 A2	01-03-2003	NICOX S.A.		
	35	WO 03/070237	08-28-2003	Warner-Lambert Company		
MG	36	WO 2004/054560 A1	07-01-2004	Warner-Lambert Company		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
MG	37	DE SARRO, G., <i>et al.</i> , "Gabapentin Potentiates the Antiseizure Activity of Certain Anticonvulsants in DBA/2 Nice", <i>European Journal of Pharmacology</i> , 1998, pp. 179-185, Vol. 349.				
	38	FELIX, R., "Voltage-Dependent Ca ²⁺ Channel $\alpha_2\delta$ Auxiliary Subunit: Structure, Function and Regulation", <i>Receptors and Channels</i> , pp. 351-361, Vol. 6.				
	39	FIELD, M.J., <i>et al.</i> , "Gabapentin and the Neurokinin ₁ Receptor Antagonist CI-1021 Act Synergistically in Two Rat Models of Neuropathic Pain", <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, pp. 730-735, Vol. 303.				
	40	KATZING, B.G., "Basic and Clinical Pharmacology," <i>Lange Medical Books</i> , p. 457, column 2, last paragraph.				
MG	41	OBERPENNING, F., <i>et al.</i> , "Interstitial Cystitis: An Update", <i>Current Opinion in Urology</i> , 2002, pp. 321-332, Vol. 12				
Examiner Signature		/Michel Graffeo/		Date Considered	01/09/2007	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO
(Revised 04/2003)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/805,977
Filing Date March 22, 2004
First Named Inventor Fraser
Group Art Unit Not yet assigned
Examiner Name Not yet assigned
Attorney Docket Number 046562/274660

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
MG	1	US-6,531,509 B2	03-11-2003	Singer <i>et al.</i>	
	2	US-6,482,837 B1	11-19-2002	Wood	
	3	US-6,329,429 B1	12-11-2001	Schrier <i>et al.</i>	
	4	US-6,255,526 B1	07-03-2001	Pesachovich <i>et al.</i>	
	5	US-6,054,482	04-25-2000	Augart <i>et al.</i>	
	6	US-5,698,549	12-16-1997	Steers <i>et al.</i>	
	7	US-2004/0037881 A1	02-26-2004	Guittard <i>et al.</i>	
	8	US-2003/0055109 A1	03-20-2003	Singer <i>et al.</i>	
	9	US-2002/0045662 A1	04-18-2002	Singer <i>et al.</i>	
	10	US-2003/0018061 A1	01-23-2003	Ogawa <i>et al.</i>	
	11	US-2002/0032235 A1	03-14-2002	Schrier <i>et al.</i>	
	12	US-2002/0091159 A1	07-11-2002	Spireas	
MG	13	US-2002/0198136 A1	12-26-2002	Mak <i>et al.</i>	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
MG	14	EP 1 289 364 A1	03-12-2003	Teva Pharmaceutical Industries Ltd.		
	15	WO 02/069906 A2	09-12-2002	Cellegy Pharmaceuticals, Inc.		
	16	WO 02/45711 A1	06-13-2002	Arakis Ltd.		
	17	WO 01/97782 A1	12-27-2001	Teva Pharmaceutical Industries Ltd.		
MG	18	WO 01/97612 A1	12-27-2001	Teva Pharmaceutical Industries Ltd.		

Examiner Signature /Michel Graffeo/ Date Considered 01/09/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO (Revised 04/2003) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/805,977	
				Filing Date	March 22, 2004	
				First Named Inventor	Fraser	
				Group Art Unit	Not yet assigned	
Examiner Name	Not yet assigned					
Sheet	2	of	2	Attorney Docket Number	046562/274660	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
MG	19	WO 00/67742 A3	11-16-2000	Warner-Lambert Company		
↓	20	WO 00/61135	10-19-2000	Warner-Lambert Company		
	21	WO 00/50027	08-31-2000	Warner-Lambert Company		
	22	WO 99/59573	11-25-1999	Warner-Lambert Company		
	MG	23	WO 99/59572	11-25-1999	Warner-Lambert Company	
OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				English Language Translation Attached
MG	24	HANSEN, H.C., "Interstitial Cystitis and the Potential Role of Gabapentin," <i>Southern Medical Journal</i> , 2000, pp. 238-242, Vol. 93(2).				
↓	25	MEGSON, I.L., "Nitric Oxide Donor Drugs," <i>Drugs of the Future</i> , 2000, pp. 701-715, Vol. 25(7).				
	26	NILVEBRANT, L., "Tolterodine and its Active 5-Hydroxymethyl Metabolite: Pure Muscarinic Receptor Antagonists," <i>Pharmacology & Toxicology</i> , 2002, pp. 260-267, Vol. 90.				
	27	SEGUCHI, <i>et al.</i> , "Expression of beta 3-Adrenoceptors in Rat Detrusor Smooth Muscle," <i>The Journal of Urology</i> , 1998, pp. 2197-2201, Vol. 159(6).				
	28	TANAKA, N., <i>et al.</i> , "Relationship Between Stereochemistry and the β_3 -Adrenoceptor Agonistic Activity of 4'-Hydroxynorephedrine Derivative as an Agent for Treatment of Frequent Urination and Urinary Incontinence," <i>J. Med. Chem.</i> , 2003, pp. 105-112, Vol. 46.				
MG	29	WANG, P.S., <i>et al.</i> , "Urinary Antispasmodic Use and the Risks of Ventricular Arrhythmia and Sudden Death in Older Patients," <i>JAGS</i> , 2002, pp. 117-124, Vol. 50.				
Examiner Signature	/Michel Graffeo/			Date Considered	01/09/2007	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.